Information for Readers
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen in the setting of lung transplantation.1 Most recipients become chronically colonized with P. aeruginosa. Previously we have demonstrated in a subgroup of patients with non-cystic fibrosis (CF) bronchiectasis who are chronically colonized with P. aeruginosa, the presence of high titres of IgG2 antibodies specific for the O-antigen of lipopolysaccharide (LPS) which impair serum-mediated killing of the cognate strain.2 In contrast to the serum bactericidal effect normally associated with antibody, this ‘inhibitory antibody’ prevented immune killing of the infecting strain.
Cardiac valve operations in patients who had undergone solid organ (kidney, liver, pancreas, heart and lung) transplantation pose unique challenges, due to the patient comorbidities and to the need for immunosuppressive therapy. Aim of this retrospective study was to present our experience with solid-organ transplanted patients who had undergone cardiac valve operation at the time or after transplantation.
Conclusions: Interval exercise was well tolerated and preferred by participants with advanced ILD. PMID: 31625781 [PubMed - as supplied by publisher]
Condition: Steroid-Refractory Acute Graft Versus Host Disease Intervention: Drug: T-Guard Sponsors: Xenikos; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program Not yet recruiting
This study analysed the effect of inhaled iloprost and oral sildenafil combination therapy (ilo-sil) on pulmonary haemodynamic parameters in patients with secondary pulmonary hypertension.
THE PERIOPERATIVE management of lung transplantation patients has advanced significantly over the past 56 years since the initial lung transplant was performed by Hardy in 1963.1,2 This advancement not only is limited to basic and clinical scientific achievements, but also extends to team-based coordination of lung transplantation care.1,3 Beginning with the isolated work of Demikhov, to the multidisciplinary Toronto Lung Transplant Group and formation of the International Society for Heart and Lung Transplantation (ISHLT), the evolution of perioperative management has been concomitant with a rise in multidisciplinary teamwork.
Cardiac rehabilitation (CR), or “cardiac rehab,” is a multifaceted, medically supervised program proven to improve heart health and outcomes in people with certain types of cardiovascular disease. CR revolves around three major components: an individualized exercise and training program, education on topics related to heart health, and stress reduction. CR is currently recommended for the following diagnoses: angina (chest pain); heart attack with or without angioplasty or bypass surgery; heart failure with reduced ejection fraction (HFrEF); and heart surgery including heart valve procedures or heart or heart/l...
Bansal et al. demonstrated that the fully magnetically levitated centrifugal-flow HeartMate3 (HM3) left ventricular assist device is associated with greater preservation of the structure of vWF HMWMs than the HeartMateII (HMII) mechanical bearing axial-flow pump.1 The findings confirm our prior work regarding the development of AVWS in VAD patients and the less distinct loss of the vWF high molecular weight multimers in HM3 patients compared with HMII patients.2,3 However, there are some differences: Bansal et al.
In this study we analyzed the quality and quantity of the structure of vWF by using mulitmer gel electrophoresis and also evaluated VWF functional activities, including platelet glycoprotein I β binding (VWF:Act LIA) and Factor VIII activity, to assess for acquired vWD (aVWD) with commercially available methods that are used in clinical practice and previously validated in congenital vWD.
Despite advances in our understanding of primary graft dysfunction (PGD) – acute lung injury in the first 72 hours after transplant – it remains a serious complication with little change in incidence over time. The main focus of the PGD literature has been on risk factor identification and modification, given limited success with therapeutic interventions.1 One of th e recipient-related risk factors that has received attention has been obesity as defined by the body mass index (BMI), in particular because BMI-related risk is potentially modifiable.